Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia.
Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the World Health Organization, currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year.
During its 10 years of existence, Brain+ has built an extensive understanding of brain functionalities and a broad platform of software technologies that can effectively assess and address the cognitive symptoms of dementia. Based on this platform, the company has developed a number of DTx dementia product candidates, of which the first, Cognitive Stimulation Therapy (CST), is in preparation for commercial launch in Germany and Denmark in 2023 in collaboration with Rox Health, a subsidiary of Roche. This partnership was signed in December 2021 as the first milestone in the strategy of Brain+ to go to market and commercially scale its digital dementia therapeutics via partnerships. The Rox Health partnership has put Brain+ firmly on the map as a core player in the DTx field.
The pharma industry is increasingly interested in DTx within Central Nervous System (CNS) diseases, and in particular within dementia and Alzheimer’s disease, and based on its growing portfolio of DTx product candidates, Brain+ has begun to more actively present its value propositions at life science partnering conferences to attract big pharma interest.
The pharma industry is increasingly interested in DTx within Central Nervous System (CNS) diseases, and in particular within dementia and Alzheimer’s disease, and based on its growing portfolio of DTx product candidates, Brain+ has begun to more actively present its value propositions at life science partnering conferences to attract big pharma interest.
I am very pleased with the growing interest that we are being met with from big pharma companies in our software solutions and DTx products for dementia. It is key for us to get access to the right resources and competencies to ensure a fast route to commercialization for our products. We are convinced that our DTx solutions offer considerable value for people living with dementia, their relatives, and the healthcare communities around them – and the interest from core pharma players in this field is also an important validation of our business potential
Kim Baden-Kristensen, CEO of Brain+
Pharma sees Digital Therapeutics as new revenue generators.
One of the major changes from pharmaceutical companies in 2022 from the last DTx Europe conference in 2019 (pre-Covid) is that more pharma companies are beginning to think of and treat Digital Therapeutics (DTx) as a profit centre in its own right, believing that DTx will be a substantial part of the industry in the future. They are thus looking for DTx solutions to be part of their product portfolio, either as a product on its own or as companion products to a pharmaceutical product.
See DTx Europe participants here: https://www.dtxeurope.com.
Examples of major DTx pharma-deals.
BehaVR and Sumitomo Pharma, April 2022
- Description: BehaVR and Sumitomo signed a deal to create virtual reality (VR) therapies to treat social anxiety disorder, generalized anxiety disorder, and major depressive disorder.
- Amount: The deal is estimated at a potential $163 million.
- Stage: Pre-commercial, product launch expected later in 2022.
- Source: https://pharmaphorum.com/digital/partnering-to-advance-digital-therapeutics-offerings/
Voluntis and Aptar, July 2021
- Description: AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, completed an acquisition of a majority stake in Voluntis (ENXTPA: ALVTX)
- Amount: Approximately €51 million.
- Stage: Commercial
- Source: https://www.businesswire.com/news/home/20210902005790/en/Aptar-Announces-the-Completion-of-the-Acquisition-of-a-Majority-Stake-in-Voluntis
Click and Boehringer Ingelheim, September 2020
- Description: In exchange for the exclusive global rights to the novel treatment, Boehringer Ingelheim agreed to provide Click with an upfront payment for R&D followed by additional payments for clinical, regulatory and commercial milestones.
- Amount: Total deal value in excess of $500 million, not counting royalties on worldwide annual net sales that Click will also be receiving.
- Stage: Before Pivotal trial.
- Source: https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-click-therapeutics-enter-collaboration-develop
